What is Theralase Technologies Inc.'s (TLT.V) StockRank?

MoatMap's StockRank for Theralase Technologies Inc. (TLT.V) is 13/100, with a Strong Sell signal. This is a composite score combining Quality (19), Value (20), and Momentum (54) factor ranks across MoatMap's 20,000+ stock universe.

Does Theralase Technologies Inc. have an economic moat?

Theralase Technologies Inc. (TLT.V) has a Quality factor score of 19/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Theralase Technologies Inc. a buy, hold, or sell?

MoatMap's current signal for Theralase Technologies Inc. (TLT.V) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Theralase Technologies Inc. in?

Theralase Technologies Inc. (TLT.V) operates in the Healthcare sector, specifically the Medical Devices industry (Canada).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

TLT.V

STRONG SELLREMOVE

Theralase Technologies Inc. · Healthcare · Canada · $45M · Avg Vol: $40K/d

StockRank

P/E (TTM)

—

ROE

-242.2%

D/E

0.2x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Theralase Technologies is a micro-cap biotech with highly speculative clinical trials and no current earnings, failing our quality and margin of safety criteria.

COMPANY DESCRIPTION

Theralase Technologies Inc. is a clinical-stage pharmaceutical and medical device company developing patented photodynamic compounds to destroy cancer cells and pathogens. The company's proprietary technology platform utilizes light-activated drugs to target and destroy cancer selectively while sparing healthy tissue. Theralase operates as a niche biotech innovator, targeting high-need oncology indications like non-muscle invasive bladder cancer.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	0.8M	0.8M	0.7M	0.6M	-10.5%
EPS	-0.02	-0.02	-0.01	-0.01	—
Shares	216.5M	228.5M	247.8M	265.0M	+22.4%
Debt	0.3M	0.3M	0.2M	0.3M	-1.1%
Equity	2.2M	1.3M	1.5M	1.3M	-16.9%
Op CF	-3.6M	-2.9M	-2.4M	-2.3M	—
Inv CF	-49,693	-26,299	-14,092	-34,535	—
Fin CF	2.1M	1.9M	2.5M	2.3M	—

PRICE (1Y)+0.0%

SMA 50SMA 200

$0.16

RSI (14)

50.0

52W High

$0.29

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

-218.0%1.5

ROE

-242.2%2.8

GP/Assets

15.8%36.7

Op. Margin

-776.9%8.3

FCF/Assets

-54.5%4.2

Piotroski

430.1

Int. Cover

-50.0x6.1

D/E Ratio

0.22x50.4

Current Ratio

1.37x21.3

Value

P/E (TTM)

—N/A

EV/EBITDA

-19.4x25.0

P/FCF

—N/A

P/B

33.6x2.8

P/S

81.0x8.0

Div Yield

—N/A

Momentum

52W High %

56%34.0

RS 6M

45%89.9

SMA 50/200

1.11x83.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

—N/A

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$45M

P/E (Forward)

-23.5x

Gross Margin

65.1%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of TLT.V are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
TLT.V	Theralase Technologies Inc.(you)	$45M	13	STRONG SELL
BLO.CN	Cannabix Technologies Inc.	$58M	11	STRONG SELL
PINK.V	Perimeter Medical Imaging AI, Inc.	$30M	9	STRONG SELL
PROF	Profound Medical Corp.	$251M	24	SELL
AIDR.CN	Rocket Doctor AI Inc.	$42M	6	STRONG SELL
EDSA	Edesa Biotech, Inc.	$61M	17	STRONG SELL
QNTM.CN	Quantum BioPharma Ltd.	$45M	2	STRONG SELL
ZEN.V	Zentek Ltd.	$50M	1	STRONG SELL
LEEF.CN	Leef Brands Inc.	$46M	29	SELL
NVRS.CN	Noveris Health Sciences Inc.	$64M	23	SELL

Peer medians: ROE -42.2% · P/E 14.3x · Gross margin 32.9%

Theralase Technologies Inc. (TLT.V) — Stock Score Summary

Theralase Technologies Inc. (TLT.V) has a MoatMap StockRank of 13/100 based on Quality (19/100), Value (20/100), and Momentum (54/100) factor scores. The current signal is STRONG SELL. Theralase Technologies is a micro-cap biotech with highly speculative clinical trials and no current earnings, failing our quality and margin of safety criteria.

Key Financial Metrics

Price	$0.16
Market Cap	$45M
P/E (Forward)	-23.50
Price/Book	33.57
Return on Equity	-242.2%
Return on Invested Capital	-218.0%
Debt/Equity	22.14
Gross Margin	65.1%
Operating Margin	-776.9%
Revenue Growth	45.4%
Free Cash Flow	$-1M

Theralase Technologies Inc. operates in the Medical Devices industry, part of the Healthcare sector (Canada).

Frequently Asked Questions

What is Theralase Technologies Inc.’s (TLT.V) StockRank?: MoatMap’s StockRank for Theralase Technologies Inc. (TLT.V) is 13/100, with a Strong Sell signal. It is a composite of Quality (19), Value (20), and Momentum (54) factor ranks across MoatMap’s 20,000+ stock universe.
Does Theralase Technologies Inc. have an economic moat?: Theralase Technologies Inc. (TLT.V) has a Quality factor score of 19/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Theralase Technologies Inc. a buy, hold, or sell?: MoatMap’s current signal for Theralase Technologies Inc. (TLT.V) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Theralase Technologies Inc. in?: Theralase Technologies Inc. (TLT.V) operates in the Healthcare sector, specifically the Medical Devices industry (Canada).